CN100581547C - Ranolazine sustained release tablets - Google Patents
Ranolazine sustained release tablets Download PDFInfo
- Publication number
- CN100581547C CN100581547C CN200710301262A CN200710301262A CN100581547C CN 100581547 C CN100581547 C CN 100581547C CN 200710301262 A CN200710301262 A CN 200710301262A CN 200710301262 A CN200710301262 A CN 200710301262A CN 100581547 C CN100581547 C CN 100581547C
- Authority
- CN
- China
- Prior art keywords
- solution
- ranolazine
- hypromellose
- product
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title claims description 47
- 229960000213 ranolazine Drugs 0.000 title claims description 46
- 239000007939 sustained release tablet Substances 0.000 title description 7
- 239000000243 solution Substances 0.000 claims description 50
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 37
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 37
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 36
- 229960003943 hypromellose Drugs 0.000 claims description 36
- 239000000047 product Substances 0.000 claims description 32
- 238000000576 coating method Methods 0.000 claims description 28
- 239000011248 coating agent Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 229920003081 Povidone K 30 Polymers 0.000 claims description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 239000013558 reference substance Substances 0.000 claims description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 229960003511 macrogol Drugs 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000004408 titanium dioxide Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000005453 pelletization Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 238000011978 dissolution method Methods 0.000 claims description 2
- 238000010812 external standard method Methods 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000011003 system suitability test Methods 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims 3
- 229960004756 ethanol Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 2
- 230000001070 adhesive effect Effects 0.000 abstract 2
- 238000012216 screening Methods 0.000 description 12
- 206010002383 Angina Pectoris Diseases 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000004004 anti-anginal agent Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000971 adrenergic beta-2 receptor antagonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229940099099 ranexa Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710301262A CN100581547C (en) | 2007-12-18 | 2007-12-18 | Ranolazine sustained release tablets |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710301262A CN100581547C (en) | 2007-12-18 | 2007-12-18 | Ranolazine sustained release tablets |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101176723A CN101176723A (en) | 2008-05-14 |
CN100581547C true CN100581547C (en) | 2010-01-20 |
Family
ID=39403244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710301262A Expired - Fee Related CN100581547C (en) | 2007-12-18 | 2007-12-18 | Ranolazine sustained release tablets |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100581547C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105616370A (en) * | 2014-11-27 | 2016-06-01 | 四川海思科制药有限公司 | Ranolazine sustained release tablet medicine composition and preparation method thereof |
TW201717919A (en) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | Ranolazine multiple compressed tablets |
CN105168166A (en) * | 2015-09-08 | 2015-12-23 | 深圳信立泰药业股份有限公司 | Coating technique of solid preparation for treating cardiovascular diseases |
WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
-
2007
- 2007-12-18 CN CN200710301262A patent/CN100581547C/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
盐酸雷诺嗪缓释片的研制及动物体内药物动力学研究. 张宇红.中国优秀硕士学位论文全文数据库电子期刊,第07期. 2006 |
盐酸雷诺嗪缓释片的研制及动物体内药物动力学研究. 张宇红.中国优秀硕士学位论文全文数据库电子期刊,第07期. 2006 * |
雷诺嗪缓释片的制备工艺筛选及其体外溶出度考察. 范治国,谢川黔.中国药方,第34期. 2007 |
雷诺嗪缓释片的制备工艺筛选及其体外溶出度考察. 范治国,谢川黔.中国药方,第34期. 2007 * |
Also Published As
Publication number | Publication date |
---|---|
CN101176723A (en) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101375849B (en) | Novel dosage form of sinomenine medicament or hydrochlorate thereof and preparation technique thereof | |
CN107669683B (en) | Pharmaceutical composition containing sitagliptin and metformin | |
CN100581547C (en) | Ranolazine sustained release tablets | |
CN103610650B (en) | A kind of isosorbide mononitrate slow-release micro-pill and preparation, preparation method | |
CN102114011B (en) | Ibuprofen sustained-release preparation and preparation method thereof | |
CN105640913B (en) | A kind of olmesartan medoxomil tablet and preparation method thereof | |
CN103156819A (en) | Benzoic acid alogliptin composition troche and preparation method thereof | |
CN112755000A (en) | Tofacitinib citrate sustained-release tablet | |
CN108635332A (en) | A kind of preparation method of voglibose particle | |
CN104758265B (en) | A kind of ranolazine sustained release tablet medicament composition and preparation method thereof | |
CN114010612B (en) | Sitagliptin and metformin double-layer sustained release tablet and preparation method thereof | |
CN101810628B (en) | Melbine glipizide tablet and preparation method thereof | |
CN106176653A (en) | A kind of pharmaceutical composition of sitagliptin | |
CN102727460A (en) | Slow-release tablets containing felodipine and metoprolo salt, and preparation method thereof | |
CN113069434A (en) | Tofacitinib citrate controlled-release capsule and preparation method thereof | |
CN1994280A (en) | Sustained-release micro-pellet of trimetazidine and preparation process thereof | |
CN106539777A (en) | A kind of methanesulfonic acid Da Lafeini slow releasing tablet and preparation method thereof | |
CN102988326B (en) | A kind of febuxostat tablet and preparation method thereof and detection method | |
CN101002781A (en) | Tablets of vacyclovir hydrochloride, and its preparing method | |
CN101342146A (en) | Preparation method of glimepiride tablet | |
CN105732517A (en) | Medicine preparation containing 5-fluorouracil drug eutectic with nicotinamide as precursor and preparation method of medicine preparation | |
CN100560069C (en) | A kind of Mitiglinide calcium preparation and detection method thereof | |
CN103396378B (en) | Stable febuxostat crystal | |
CN106580909B (en) | Solid pharmaceutical composition containing sarpogrelate hydrochloride | |
CN105616370A (en) | Ranolazine sustained release tablet medicine composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., Free format text: FORMER OWNER: YAN JIE Effective date: 20120213 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120213 Address after: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee after: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee before: Yan Jie |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100120 Termination date: 20171218 |
|
CF01 | Termination of patent right due to non-payment of annual fee |